Right on the heels of a PhIII failure, Merck neuroscience doubles down with a new drug targeting tau

Merck isn’t letting its first big Phase III failure in Alzheimer’s get in the way of its ambitions in the field. The pharma giant just grabbed worldwide rights …

Link to Full Article

Pin It on Pinterest

Share This

Join Our Newsletter

Sign up to our mailing list to receive the latest news and updates about homeAI.info and the Informed.AI Network of AI related websites which includes Events.AI, Neurons.AI, Awards.AI, and Vocation.AI

You have Successfully Subscribed!